United Therapeutics (NASDAQ:UTHR) is set to issue its quarterly earnings data before the market opens on Tuesday, February 20th. Analysts expect the company to announce earnings of $3.59 per share for the quarter.
United Therapeutics (NASDAQ:UTHR) opened at $129.50 on Tuesday. The firm has a market cap of $5,600.00, a price-to-earnings ratio of 11.42 and a beta of 1.26. United Therapeutics has a fifty-two week low of $112.01 and a fifty-two week high of $169.89.
UTHR has been the topic of a number of recent analyst reports. HC Wainwright restated a “hold” rating and set a $95.00 target price on shares of United Therapeutics in a report on Thursday, October 26th. Cowen restated a “hold” rating and set a $129.00 target price on shares of United Therapeutics in a report on Friday, October 27th. ValuEngine upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, November 30th. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Finally, TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a research report on Friday, December 15th. Four equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $140.27.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.